Evogene Ltd. (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.
Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.
EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.
EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.
This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.
One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.
The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.
Please note that due to factors including low market capitalization and/or insufficient public float, we consider EVGN to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.